IMACS恶性肿瘤筛查指南在特发性炎性肌病中的国际多中心审计
该国际多中心回顾性审计纳入795例特发性炎性肌病患者,按IMACS风险分层评估历史筛查与指南推荐的差距。结果显示仅少数患者完成全套推荐筛查,10.8%在诊断后3年内发生恶性肿瘤,且多集中于高风险组。抗TIF1γ阳性、吸烟、盗汗和年龄增长与癌症独立相关。
要点
- IMACS风险分层能区分恶性肿瘤风险,但历史筛查强度普遍不足。
- 抗TIF1γ阳性、吸烟、盗汗及年龄增长是癌症独立预测因素。
- 高风险特征越多癌症风险越高,低风险特征越多风险越低。
核心结论
- 观察到的癌症分布与IMACS风险分层逻辑一致,但筛查强度差异使预测效度无法正式评估。
研究设计与样本
- 回顾性多中心研究,纳入来自7个国家/地区8个中心的795例特发性炎性肌病患者,按IMACS风险类别分层并比较历史筛查与指南推荐。
主要发现
- 795例患者中高风险、中风险和标准风险分别占51.7%、37.9%和10.4%。
- 完成全套IMACS推荐检测的比例在高风险组为6.2%、中风险组为2.7%、标准风险组为11.1%。
- 诊断后3年内86例(10.8%)发生恶性肿瘤,其中77.4%在高风险组、22.6%在中风险组,标准风险组未检出。
- 抗TIF1γ阳性(OR 4.64,95%CI 2.35-9.16,p<0.001)、吸烟(OR 3.00,95%CI 1.64-5.50,p<0.001)、盗汗(OR 12.76,95%CI 2.72-59.87,p=0.001)和年龄增长(每岁OR 1.05,95%CI 1.03-1.07,p<0.001)与癌症独立相关。
- 每增加一个高风险特征癌症风险增加(OR 1.70),每增加一个低风险特征风险降低(OR 0.76);筛查不足者免疫介导坏死性肌病比例较低(5.6% vs 14.3%,p=0.005),抗TIF1γ阳性率较低(6.8% vs 31.4%,p<0.001)。
关键数值与推荐
- IMACS指南推荐根据风险分层进行恶性肿瘤筛查,但原文未列出具体筛查项目或时间阈值。
临床怎么用
- 临床应依据IMACS风险分层对特发性炎性肌病患者进行恶性肿瘤筛查,尤其关注抗TIF1γ阳性、吸烟、盗汗及高龄患者。
局限性
- 历史筛查强度差异大,无法正式评估IMACS框架的预测效度;需前瞻性纵向研究评估累积风险、年龄阈值、筛查依从性和结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Consensus guidelines for malignancy screening in idiopathic inflammatory myopathy (IIM) were recently published by the International Myositis Assessment and Clinical Studies (IMACS) working group. This international multicentre study audited historical cancer screening practices against IMACS recommendations and examined the distribution of observed malignancies across IMACS-defined risk categories in a real-world cohort. METHODS: This retrospective study included patients with IIM from eight centres across seven countries/regions. Patients were stratified using IMACS-defined cancer risk categories. Historical screening was compared with the guideline recommendations. Multivariable logistic regression identified predictors of cancer and underscreening. RESULTS: Of the 795 patients (72.3% female), 51.7%, 37.9% and 10.4% were classified as high risk, moderate risk and standard risk, respectively. Across all sites, few high-risk (6.2%), moderate-risk (2.7%) and standard-risk (11.1%) patients underwent a full panel of IMACS-recommended tests. Within 3 years of diagnosis, 86 patients (10.8%) developed malignancy. Among observed cancers, 77.4% occurred in high-risk and 22.6% in moderate-risk patients, with none detected in the standard-risk group. Anti-transcription intermediary factor 1-gamma (TIF1γ) positivity (OR 4.64, 95% CI 2.35 to 9.16, p<0.001), smoking (OR 3.00, 95% CI 1.64 to 5.50, p<0.001), night sweats (OR 12.76, 95% CI 2.72 to 59.87, p=0.001) and increasing age (OR 1.05 95% CI 1.03 to 1.07 per year, p<0.001) were independently associated with cancer, whereas anti-Mi2 antibodies and non-dermatomyositis subtypes were protective. Cancer risk increased with each additional high-risk feature (OR 1.70) and decreased with each low-risk feature (OR 0.76). Underscreened individuals had lower rates of immune-mediated necrotising myopathy (5.6% vs 14.3%, p=0.005) and anti-TIF1γ positivity (6.8% vs 31.4%, p<0.001). CONCLUSION: Observed cancer distribution across IMACS risk categories was consistent with the framework's stratification logic, but differential screening intensity precludes formal assessment of predictive validity. Variation between historical practice and current recommendations underscores the need for continued education and prospective longitudinal studies to assess cumulative risk, age thresholds, screening uptake and outcomes in real-world clinical settings.
引用
- Day J, Minikumari Rahulan L, Shinjo SK, et al. Multicentre international audit of IMACS malignancy screening guidelines in idiopathic inflammatory myopathies: insights from the myositis audit and research collaborative group. RMD Open. 2026. PMID: 42457211. doi:10.1136/rmdopen-2025-006373
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。